News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO) Intends to Appeal Adverse Ruling in Prandin® (repaglinide) Patent Case


1/20/2011 8:48:11 AM

BAGSVæRD, DENMARK--(Marketwire - January 19, 2011) -







Company Announcement no 2 2011: http://hugin.info/2013/R/1480941/416315.pdf




This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1480941]


Further information:
Media:

Mike Rulis
Tel: (+45) 3079 3573
Email Contact


In North America:
Ken Inchausti
Tel: (+1) 609 514 8316
Email Contact


Investors:

Klaus Bulow Davidsen
Tel: (+45) 4442 3176
Email Contact


Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
Email Contact


Jannick Lindegaard
Tel: (+45) 4442 4765
Email Contact


In North America:
Hans Rommer
Tel: (+1) 609 919 7937
Email Contact


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES